OTCMKTS:IPHYF Innate Pharma (IPHYF) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free IPHYF Stock Alerts $2.65 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$2.65▼$2.6550-Day Range$2.34▼$2.8452-Week Range$2.30▼$3.37VolumeN/AAverage Volume65 shsMarket Capitalization$212.56 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get Innate Pharma alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Innate Pharma Stock (OTCMKTS:IPHYF)Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Read More IPHYF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IPHYF Stock News HeadlinesApril 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Innate Pharma Amidst Promising Platforms and Strategic Growth PotentialMarch 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Innate Pharma SA (OtherIPHYF), Medios AG (OtherMEDOF) and Tecan Group AG (OtherTCHBF)April 24, 2024 | GoldenCrest Metals (Ad)Emergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.February 26, 2024 | benzinga.comInnate Pharma Stock (OTC:IPHYF), Insider Trading ActivityFebruary 4, 2024 | markets.businessinsider.comInnate Pharma SA (IPHYF) Receives a Hold from Kepler CapitalJanuary 11, 2024 | seekingalpha.comInnate Pharma: Worth A Deeper LookJanuary 6, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Innate Pharma SA (OtherIPHYF), Amgen (AMGN) and Regeneron (REGN)January 4, 2024 | marketwatch.comInnate Pharma Up 4% After FDA Lifts Partial Clinical Hold on LacutamabApril 24, 2024 | GoldenCrest Metals (Ad)Emergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.December 19, 2023 | msn.comInnate Pharma and Sanofi to license natural killer cell engagerDecember 14, 2023 | markets.businessinsider.comBuy Rating for Innate Pharma Backed by Promising Lacutamab Clinical Results and Regulatory ProspectsNovember 27, 2023 | finance.yahoo.comInnate Pharma to Host Virtual KOL Event on LacutamabNovember 7, 2023 | finance.yahoo.comInnate Pharma Announces Conference Call for Third Quarter 2023 Business UpdateOctober 27, 2023 | finance.yahoo.comInnate Pharma Announces Its Participation to Upcoming Investor ConferencesOctober 16, 2023 | finance.yahoo.comInnate Pharma Announces Abstracts Selected for ESMO Congress 2023October 5, 2023 | marketwatch.comInnate Pharma Shares Fall Premarket on FDA Partial Study HoldOctober 5, 2023 | msn.comRegulatory Hurdle For Innate Pharma's Blood Cancer StudiesOctober 5, 2023 | markets.businessinsider.comInnate Pharma Says FDA Places Partial Clinical Hold On Lacutamab IND; Stock Down 10%September 22, 2023 | finance.yahoo.comInnate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023July 11, 2023 | finance.yahoo.comFirst Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple MyelomaJuly 7, 2023 | finance.yahoo.comNumber of Shares and Voting Rights of Innate Pharma as of July 1, 2023June 18, 2023 | markets.businessinsider.comKepler Capital Reaffirms Their Hold Rating on Innate Pharma SA (IPHYF)June 8, 2023 | marketwatch.comADRs End Higher, Innate Pharma and Medigus Trade ActivelyJune 8, 2023 | marketwatch.comInnate Pharma Shares Rise 8% After Cancer Treatment Gets Fast Track DesignationMay 26, 2023 | finance.yahoo.comInnate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AMLMay 15, 2023 | finance.yahoo.comInnate Pharma to Present IPH6501 Preclinical Data at The EHA 2023 CongressMay 11, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Innate Pharma (IPHA)See More Headlines Receive IPHYF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolOTCMKTS:IPHYF Previous SymbolNASDAQ:IPHYF CUSIPN/A CIK1598599 Webwww.innate-pharma.com Phone(343) 030-3030Fax33-04-30-30-30-00Employees179Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.73 Quick Ratio3.73 Sales & Book Value Annual Sales$66.71 million Price / Sales3.19 Cash FlowN/A Price / Cash FlowN/A Book Value$0.70 per share Price / Book3.79Miscellaneous Outstanding Shares80,210,000Free Float54,632,000Market Cap$212.56 million OptionableNot Optionable Beta1.12 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Herve Brailly Ph.D. (Age 63)Co-Founder, Interim CEO & Chairman of Executive Board Mr. Yannis Morel Ph.D. (Age 51)Executive VP, COO & Member of Executive Board Comp: $382.41kDr. François Romagné Ph.D. (Age 60)Founder Mr. Eric Vivier D.V.M. (Age 60)M.B.A., Ph.D., Founder, Senior VP & Chief Scientific Officer Dr. Marc Bonneville Ph.D. (Age 64)Founder Mr. Jean Jacques Fournié Ph.D.FounderMr. Alessandro Moretta M.D.Ph.D., FounderMr. Frederic Lombard M.B.A. (Age 49)Senior VP & CFO Dr. Sonia Quaratino M.D. (Age 57)Ph.D., Executive VP, Chief Medical Officer & Member of Executive Board Mr. Arvind SoodExecutive VP, President of US Operations & Member of Executive BoardMore ExecutivesKey CompetitorsLineage Cell TherapeuticsNYSEAMERICAN:LCTXElevation OncologyNASDAQ:ELEVCompass TherapeuticsNASDAQ:CMPXPoseida TherapeuticsNASDAQ:PSTXX4 PharmaceuticalsNASDAQ:XFORView All Competitors IPHYF Stock Analysis - Frequently Asked Questions How have IPHYF shares performed in 2024? Innate Pharma's stock was trading at $2.84 on January 1st, 2024. Since then, IPHYF shares have decreased by 6.7% and is now trading at $2.65. View the best growth stocks for 2024 here. How do I buy shares of Innate Pharma? Shares of IPHYF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:IPHYF) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe Greatest Bull Market in Crypto History…Weiss RatingsNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.